Literature DB >> 27113164

Antigen nature and complexity influence human antibody light chain usage and specificity.

Kenneth Smith1, Hemangi Shah2, Jennifer J Muther3, Angie L Duke3, Kathleen Haley3, Judith A James4.   

Abstract

Human antibodies consist of a heavy chain and one of two possible light chains, kappa (κ) or lambda (λ). Here we tested how these two possible light chains influence the overall antibody response to polysaccharide and protein antigens by measuring light chain usage in human monoclonal antibodies from antibody secreting cells obtained following vaccination with Pneumovax23. Remarkably, we found that individuals displayed restricted light chain usage to certain serotypes and that lambda antibodies have different specificities and modes of cross-reactivity than kappa antibodies. Thus, at both the monoclonal (7 kappa, no lambda) and serum levels (145μg/mL kappa, 2.82μg/mL lambda), antibodies to cell wall polysaccharide were nearly always kappa. The pneumococcal reference serum 007sp was analyzed for light chain usage to 12 pneumococcal serotypes for which it is well characterized. Similar to results at the monoclonal level, certain serotypes tended to favor one of the light chains (14 and 19A, lambda; 6A and 23F, kappa). We also explored differences in light chain usage at the serum level to a variety of antigens. We examined serum antibodies to diphtheria toxin mutant CRM197 and Epstein-Barr virus protein EBNA-1. These responses tended to be kappa dominant (average kappa-to-lambda ratios of 4.52 and 9.72 respectively). Responses to the influenza vaccine were more balanced with kappa-to-lambda ratio averages having slight strain variations: seasonal H1N1, 1.1; H3N2, 0.96; B, 0.91. We conclude that antigens with limited epitopes tend to produce antibodies with restricted light chain usage and that in most individuals, antibodies with lambda light chains have specificities different and complementary to kappa-containing antibodies.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anti-polysaccharide; Human monoclonal antibodies; Kappa light chain; Lambda light chain; Light chain usage

Mesh:

Substances:

Year:  2016        PMID: 27113164      PMCID: PMC4876604          DOI: 10.1016/j.vaccine.2016.04.040

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  31 in total

Review 1.  Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides.

Authors:  Catherine M Wernette; Carl E Frasch; Dace Madore; George Carlone; David Goldblatt; Brian Plikaytis; William Benjamin; Sally A Quataert; Steve Hildreth; Daniel J Sikkema; Helena Käyhty; Ingileif Jonsdottir; Moon H Nahm
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

2.  The glycine-alanine repeating region is the major epitope of the Epstein-Barr nuclear antigen-1 (EBNA-1).

Authors:  H Rumpold; G H Rhodes; P L Bloch; D A Carson; J H Vaughan
Journal:  J Immunol       Date:  1987-01-15       Impact factor: 5.422

3.  Influence of the isotype of the light chain on the properties of IgG.

Authors:  Ramon F Montaño; Sherie L Morrison
Journal:  J Immunol       Date:  2002-01-01       Impact factor: 5.422

4.  Human monoclonal antibodies generated following vaccination with AVA provide neutralization by blocking furin cleavage but not by preventing oligomerization.

Authors:  Kenneth Smith; Sherry R Crowe; Lori Garman; Carla J Guthridge; Jennifer J Muther; Emily McKee; Nai-Ying Zheng; A Darise Farris; Joel M Guthridge; Patrick C Wilson; Judith A James
Journal:  Vaccine       Date:  2012-03-14       Impact factor: 3.641

5.  Altered immune response to glycine-rich sequences of Epstein-Barr nuclear antigen-1 in patients with rheumatoid arthritis and systemic lupus erythematosus.

Authors:  J Petersen; G Rhodes; J Roudier; J H Vaughan
Journal:  Arthritis Rheum       Date:  1990-07

6.  B cell receptor light chain repertoires show signs of selection with differences between groups of healthy individuals and SLE patients.

Authors:  Nathan Schoettler; Dongyao Ni; Martin Weigert
Journal:  Mol Immunol       Date:  2012-04-18       Impact factor: 4.407

7.  Lupus-like autoantibody development in rabbits and mice after immunization with EBNA-1 fragments.

Authors:  Brian D Poole; Timothy Gross; Shannon Maier; John B Harley; Judith A James
Journal:  J Autoimmun       Date:  2008-10-11       Impact factor: 7.094

8.  Restriction of immunoglobulin heterogeneity, autoimmunity and serum protein levels in aged people.

Authors:  W Riesen; H Keller; F Skvaril; A Morell; S Barandun
Journal:  Clin Exp Immunol       Date:  1976-11       Impact factor: 4.330

9.  Antigen receptor engagement turns off the V(D)J recombination machinery in human tonsil B cells.

Authors:  E Meffre; F Papavasiliou; P Cohen; O de Bouteiller; D Bell; H Karasuyama; C Schiff; J Banchereau; Y J Liu; M C Nussenzweig
Journal:  J Exp Med       Date:  1998-08-17       Impact factor: 14.307

10.  Functional anergy in a subpopulation of naive B cells from healthy humans that express autoreactive immunoglobulin receptors.

Authors:  J Andrew Duty; Peter Szodoray; Nai-Ying Zheng; Kristi A Koelsch; Qingzhao Zhang; Mike Swiatkowski; Melissa Mathias; Lori Garman; Christina Helms; Britt Nakken; Kenneth Smith; A Darise Farris; Patrick C Wilson
Journal:  J Exp Med       Date:  2008-12-22       Impact factor: 14.307

View more
  5 in total

1.  Development of an Extended-Specificity Multiplex Immunoassay for Detection of Streptococcus pneumoniae Serotype-Specific Antigen in Urine by Use of Human Monoclonal Antibodies.

Authors:  Seyi D Eletu; Carmen L Sheppard; Elizabeth Thomas; Kenneth Smith; Priya Daniel; David J Litt; Wei Shen Lim; Norman K Fry
Journal:  Clin Vaccine Immunol       Date:  2017-12-05

2.  Development of a Phage Display Panning Strategy Utilizing Crude Antigens: Isolation of MERS-CoV Nucleoprotein human antibodies.

Authors:  Chia Chiu Lim; Patrick C Y Woo; Theam Soon Lim
Journal:  Sci Rep       Date:  2019-04-15       Impact factor: 4.379

Review 3.  Insights From Analysis of Human Antigen-Specific Memory B Cell Repertoires.

Authors:  Hemangi B Shah; Kenneth Smith; Jonathan D Wren; Carol F Webb; Jimmy D Ballard; Rebecka L Bourn; Judith A James; Mark L Lang
Journal:  Front Immunol       Date:  2019-01-15       Impact factor: 7.561

4.  Rational antibody design for undruggable targets using kinetically controlled biomolecular probes.

Authors:  Carolina L Trkulja; Oscar Jungholm; Max Davidson; Kent Jardemark; Monica M Marcus; Jessica Hägglund; Anders Karlsson; Roger Karlsson; Joseph Bruton; Niklas Ivarsson; Sreesha P Srinivasa; Alexandra Cavallin; Peder Svensson; Gavin D M Jeffries; Maria-Nefeli Christakopoulou; Anna Reymer; Anaswara Ashok; Gabriella Willman; Daniela Papadia; Emma Johnsson; Owe Orwar
Journal:  Sci Adv       Date:  2021-04-16       Impact factor: 14.136

5.  Convergent antibody evolution and clonotype expansion following influenza virus vaccination.

Authors:  David Forgacs; Rodrigo B Abreu; Giuseppe A Sautto; Greg A Kirchenbaum; Elliott Drabek; Kevin S Williamson; Dongkyoon Kim; Daniel E Emerling; Ted M Ross
Journal:  PLoS One       Date:  2021-02-22       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.